# Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）

Study · id `cardio:ct-nct07027774` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07027774](<https://clinicaltrials.gov/study/NCT07027774>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07027774

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 429 participants.

## Technical summary

Registry record NCT07027774. Randomized; no masking; primary purpose treatment. Start 2025-07-10 (anticipated); primary completion 2027-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 429 participants (planned count; ClinicalTrials.gov record NCT07027774, source copy `cardio:ctgov-nct07027774-2025-06-18`, retrieved 2026-10-26)
- Planned start: 2025-07-10 (anticipated) (ClinicalTrials.gov record NCT07027774, source copy `cardio:ctgov-nct07027774-2025-06-18`, retrieved 2026-10-26)
- Primary completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07027774, source copy `cardio:ctgov-nct07027774-2025-06-18`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07027774, source copy `cardio:ctgov-nct07027774-2025-06-18`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07027774-2025-06-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）
- Condition: Chronic Kidney Disease Stage 4
- Intervention (Drug): Henagliflozin 5 mg Group
- Intervention (Drug): Henagliflozin 10 mg Group
- Intervention (Drug): Conventional therapy group
- Lead sponsor: First Affiliated Hospital of Wannan Medical College
- Lead sponsor class: OTHER
- Collaborator: Jiangsu HengRui Medicine Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Wannan Medical College (`cardio:org-first-affiliated-hospital-of-wannan-medical-college`)
- Registry lists this organization as a collaborator: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: fc224c9472fe72d7712e49761ba2025fb492a7d2a8f914157d04642277f5c2db
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
